Active Management Of Risk In Pregnancy At Term to Reduce Rate of Cesarean Deliveries

This study has been terminated.
Sponsor:
Information provided by:
Albert Einstein Healthcare Network
ClinicalTrials.gov Identifier:
NCT00598260
First received: January 10, 2008
Last updated: May 9, 2011
Last verified: May 2011
  Purpose

This is a prospective randomized cohort study of obstetric patients from Paley clinic at AEMC and from other affiliated obstetric clinics.

This study will try to determine if active management of risks in pregnancy at term by inducing patients will not decrease the cesarean delivery rate or change neonatal outcomes.

The outcomes that will be measured include cesarean delivery rate, meconium, Apgar scores and admissions to the NICU.


Condition Intervention
Pregnancy
Procedure: induction of labor

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Active Management Of Risk In Pregnancy At Term - a Prospective Study

Resource links provided by NLM:


Further study details as provided by Albert Einstein Healthcare Network:

Primary Outcome Measures:
  • cesarean delivery rate [ Time Frame: prospective: 06.2006 to 06.2008 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • admissions to NICU during same hospitalization [ Time Frame: prospective. 06.2006 - 06.2008 ] [ Designated as safety issue: Yes ]
  • APGAR scores at one and five minutes [ Time Frame: prospective. 06.2006 - 06.2008 ] [ Designated as safety issue: Yes ]
  • meconium [ Time Frame: prospective. 06.2006 - 06.2008 ] [ Designated as safety issue: No ]

Enrollment: 222
Study Start Date: June 2006
Study Completion Date: October 2009
Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1- study group
study group - induction of labor at optimal time of delivery between 38 weeks and 41 weeks.
Procedure: induction of labor
study group - induction of labor at optimal time of delivery between 38 weeks and 41 weeks.
No Intervention: 2 - control group
control group

Detailed Description:

The study will include patients who have their prenatal care at the Paley clinic in AEMC, where the residents provide the prenatal care with supervision of OBGYN attending physicians, or at other affiliated clinics that are staffed by care givers from our OBGYN department.

Patients at our obstetric clinics are scheduled for weekly visits starting at 36 weeks. At 36 to 37 weeks of gestation, or earlier, each patient will be offered to participate in the study. Those who refuse will continue to have the standard care and will not be considered as part of the study. Those who wish to participate in the study will be consented and will then be randomly assigned to the control group or to the AMOR-IPAT group with a ratio of 2:1.

Risk factors will be identified for each patient participating in the study at the gestational age of 36 to 37 weeks (using the digichart system, the medical records and questioners) and the upper limit of the optimal time of delivery will be calculated for each patient, according to the method used by the UPenn group, with the time always being at least 38 weeks and no more then 41 weeks.

Patients from the AMOR-IPAT group will be scheduled for induction of labor on the morning of the day of the calculated upper limit (plus or minus 2 days).

To try and eliminate biases, a uniform method of induction will be applied to all the patients participating in the study, no matter the group or the reason for the induction. The induction will be performed with misoprostol 25mcg intravaginally every four hours (to a maximum of three doses) for a Bishop score of 4 or less and as long as there is no tachysystole which will be defined as six or more uterine contractions in ten minutes in consecutive ten minute intervals. The misoprostol will be followed by a foley bulb inflated with 80 cc of fluid if the cervix is still not favorable after three doses or when tachysystole develops. Once the cervix is favorable induction will be continued with high dose oxytocin (starting dose of six milliunits with increments of four milliunits every thirty minutes), which is associated with less cesarean deliveries for dystocia than the low dose.

Anesthesia will be applied according to the patient's wish, without limiting epidural anesthesia to a certain degree of dilatation.

After delivery information will be collected from the charts and the two groups will be compared regarding the incidence of cesarean deliveries, but also regarding intrapartum variables and major outcomes.

The Student t test and the Wilcoxon rank sum test will be used to compare continuous demographic characteristics, past medical and surgical historic features and obstetric risk factors that will be present in the two study groups. Universal chi squared tests will be used to compare levels of various dichotomous variables.

Statistical significance is defined as a probability value of less than 0.05. Using a power analysis and by assuming a cesarean delivery rate of 20% in the control group and a change of 13% (as shown in the original study) we will need 191 patients in the control group and 96 in the study group.

All data will be collected by staff of the OBGYN department and maintained on departmental secured password limited database. Obstetrical prenatal data is maintained on HIPPA compliant password protected electronic medical records.

  Eligibility

Ages Eligible for Study:   16 Years to 40 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • patients with singleton pregnancies
  • at least one prenatal visit at one of our clinics
  • an ultrasonogram confirming the dates within the first 22 weeks
  • no maternal or fetal problems before 37 weeks and 5 days of gestation that mandated cesarean delivery.

Exclusion Criteria:

  • a delivery before 37 weeks and 5 days of gestation
  • a previous cesarean delivery (one or more)
  • a history of any other uterine surgeries that are a contraindication for a vaginal delivery.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00598260

Locations
United States, Pennsylvania
Albert Einstein Medical Center
Philadelphia, Pennsylvania, United States, 19141
Sponsors and Collaborators
Albert Einstein Healthcare Network
Investigators
Study Chair: Arnold Cohen, MD Albert Einstein Medical Center
Principal Investigator: Shai M Pri-Paz, MD Albert Einstein Medical Center
  More Information

No publications provided

Responsible Party: Shai Pri-Paz, Albert Einstein Medical Center
ClinicalTrials.gov Identifier: NCT00598260     History of Changes
Other Study ID Numbers: (H)N-2957
Study First Received: January 10, 2008
Last Updated: May 9, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by Albert Einstein Healthcare Network:
active management
induction of labor
cesarean delivery
Cesarean

ClinicalTrials.gov processed this record on October 22, 2014